Alzheimer’s Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners

[1] Petersen RC(2005)Mild cognitive impairment as a clinical entity and treatment target Arch Neurol 62 1160-3

[2] Morris JC(2013)Making sense of nonsense: experiences of mild cognitive impairment Sociol Health Illn 35 130-46

[3] Beard RL(2009)Mild cognitive impairment: ten years later Arch Neurol 66 1447-55

[4] Neary TM(2006)Ten-year risk of dementia in subjects with mild cognitive impairment Neurology 67 1201-7

[5] Petersen RC(2011)The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 270-9

[6] Roberts RO(2015)Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Brain 138 1327-38

[7] Knopman DS(2018)Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting JAMA Neurol 75 970-79

[8] Visser PJ(2011)Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 275-83

[9] Kester A(2008)Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 129-35

[10] Jolles J(2011)Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology Arch Neurol 68 1398-403

[1] Petersen RC(2005)Mild cognitive impairment as a clinical entity and treatment target Arch Neurol 62 1160-3

[2] Morris JC(2013)Making sense of nonsense: experiences of mild cognitive impairment Sociol Health Illn 35 130-46

[3] Beard RL(2009)Mild cognitive impairment: ten years later Arch Neurol 66 1447-55

[4] Neary TM(2006)Ten-year risk of dementia in subjects with mild cognitive impairment Neurology 67 1201-7

[5] Petersen RC(2011)The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 270-9

[6] Roberts RO(2015)Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Brain 138 1327-38

[7] Knopman DS(2018)Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting JAMA Neurol 75 970-79

[8] Visser PJ(2011)Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 275-83

[9] Kester A(2008)Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 129-35

[10] Jolles J(2011)Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology Arch Neurol 68 1398-403